Elikya Therapeutics is a biotechnology start-up part of the Nexus of Landmark BioVentures. The company is developing new generation of Antibody Drug Conjugates (ADCs) in oncology using its proprietary and first-in-class toxic payloads. The company is a spin-off of the University Paris Saclay, France (UPS) and the Gustave Roussy Institute (IGR) in France. Through its academic founders, Elikya Therapeutics is leveraging more than 15 years of world recognized research. The team is also composed of seasoned team of biotech industrials with more than 35 years of experience in the biotech and pharma industry.
The company is currently is hosted at the incubator, Quest for Health (SEMIA) in Strasbourg, France.
Elikya Therapeutics is focused on the development of First-in-Class toxic payloads for ADC and intra-tumoral therapies with differentiated mechanism of action against cancer cells and tumoral micro-environment.
Elikya Therapeutics is part of the nexus of Landmark Bioventures. (www-landmarkbioventures.com)
Company Details
- Employees
- 2
- Founded
- -
- Address
- 11, Rue De L'académie, Strasbourg,grand Est 67000,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Strasbourg, Grand Est
Elikya Therapeutics Questions
Elikya Therapeutics's website is http://www.elikya-therapeutics.com
Elikya Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/elikya-therapeutics
Elikya Therapeutics has
2 employees.
View email and phone details for 2
employees at Elikya Therapeutics.
Elikya Therapeutics's industry is
Biotechnology Research
Elikya Therapeutics's top competitors are
Cure51,
Recobia Therapeutics,
Panntherapi,
Carla Biotherapeutics,
Weezion,
Landmark Bioventures Ag,
Duhn Therapeutics,
Spima Therapeutics,
Kekkan Biologics,
Roca Therapeutics.
Elikya Therapeutics's categories are Biotechnology Research
Elikya Therapeutics's founding year is 2022
